Prosecution Insights
Last updated: July 17, 2026
Application No. 18/553,456

INSECT PEST BAIT COMPOSITION WITH ISOCYCLOSERAM AND METHOD FOR CONTROLLING INSECT PESTS

Final Rejection §103
Filed
Sep 29, 2023
Priority
Mar 31, 2021 — EU 21166425.5 +1 more
Examiner
MAEWALL, SNIGDHA
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta AG
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
7m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
625 granted / 1064 resolved
-1.3% vs TC avg
Moderate +10% lift
Without
With
+10.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
48 currently pending
Career history
1114
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
68.6%
+28.6% vs TC avg
§102
1.4%
-38.6% vs TC avg
§112
1.7%
-38.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1064 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Previous Rejections Applicants' arguments, filed 01/08/26 have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-4, 6-13 and 15-27 are rejected under 35 U.S.C. 103 as being unpatentable over Reinhard et al. (WO 2018/234478 A1) in view of Sikuljak et al. (WO 2016/166252 A1). Reinhard et al. discloses pesticidal compositions comprising a pyrazole carboxamide compound (A) and isocycloseram (see cpd. B1b) in a weight ratio of 1000:1 to 1:1000 (see claim 4; preferred mixtures A-4 to A-6). The composition may be used in form of a bait formulation. The bait formulation is a liquid, a solid or a semi-solid preparation, such as a gel. It has to be sufficiently attractive to insects (such as ants, termites, wasps, flies, mosquitoes, crickets or cockroaches) to incite them to eat it. The attractiveness is modulated using feeding stimulants, flavors and sex pheromones. The bait compositions comprise 0.0001 to 15 wt.%, such as 0.001 to 5 wt.-%, of the active compound. This amount provides guidance to one of ordinary skill in the art to manipulate the amount for insecticidal bait purposes. The bait may comprise bittering agents (p. 25, lines 11-19 and lines 40-44). Since the document by Reinhard defines specific mixtures comprising isocycloseram, there is only to be made a single selection in the list of formulation types, namely the selection of using the mixture in form of a bait. Reinhard teaches use of protein, see page 8, lines 14-15. Reinhard teaches use of sugar-based surfactants and sugar on page 21, lines 20, 25 and page 39, line 43. Reinhard teaches use of yeast, page 35, lines 13. Solid carriers include salts, see page 21, lines 1-9. Reinhard teaches use of potassium sorbate, see page 35, lines 20-21. Reinhard does not teach use of polysaccharide or a vegetable. Sikuljak discloses methods for combatting insect pests using broflanilide (cpd. 1) or the active compound desmethyl-broflanilide (cpd. la). The compounds can be formulated as bait (claims 1 and 16). The bait formulation is a liquid, a solid or a semi- solid preparation, such as a gel. It has to be sufficiently attractive to insects (such as ants, termites, wasps, flies, crickets, bed bugs or cockroaches) to incite them to eat it. The attractiveness is modulated using feeding stimulants, food stimulants and sex pheromones. Suitable components encompass polysaccharides, proteins and decaying parts of plants or insects. The bait compositions comprise 0.001 to 15 wt.-%, such as 0.001 to 5 wt.-%, of the active compound. The bait may comprise bittering agents (p. 17, lines 9-11; p. 34, lines 24; p. 35, lines 28). Sikuljak does not disclose bait compositions comprising isocycloseram. It would have been obvious to one of ordinary skill before the effective filing date of the claimed invention to have utilized bait material made up of protein, carbohydrate or vegetable and use it with the composition of Rheinhard et al. One of ordinary skill would be motivated to do so because Sikuljak discloses methods for combatting insect pests by attracting with baits and the attractiveness is modulated with feeding stimulants including protein, polysaccharide and plant and insect decays. Since the references make obvious the claimed insect pest bait composition, the loading rate and the average return would necessarily be present because property cannot be separated from the chemistry of the composition. Applicant argues that the combination of refences do not show obviousness for the claimed invention. These arguments are not persuasive. As discussed in the rejections above, Rheinhard teaches pesticidal composition which can be used as insect bait composition comprising isocycloseram and Sikuljak provides motivation to use protein, carbohydrate or vegetable to be used in bait formulation. Applicant argues that the data in the Specification as filed illustrates "that insect baits which comprise isocyloseram as an insecticidal active substance are particularly suitable for controlling insect pests and insect populations including social or communal insect pests." Example 4 (Specification at 13-14) demonstrates that isocycloseram-containing baits, achieve higher loading rates, lower return rates, and superior long-term control of Atta bisphaerica compared to the commercial standard (Mirex-S). Specifically, isocycloseram baits had an average loading rate of 97.03%, a return rate below 7% (versus 10-15% for Mirex-S), regardless of the dosage and concentration of active ingredient. The control efficiency after opening the nests in the excavation of the anthills showed that the treatments isocyloseram - 0.2% (10 and 12 g) and 0.3% (6, 10 and 12 g) have control higher than 84%, outperforming Mirex-S. These arguments are not persuasive to overcome the rejections of record. Applicant has not provided comparison with the closest prior art which teaches insecticidal bait formulation comprising isocycloseram. No comparative experiments have been presented, and it is unclear whether there is any difference between the inventive formulation and the known isocycloseram comprising formulation to be used as insect bait formulation as taught by the prior art. The tests used in a comparison must be made under identical conditions except for the novel features of the invention. See MPEP 716.02(e). And as such a comparison has not been presented, the argument are not found persuasive. Action is final THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SNIGDHA MAEWALL whose telephone number is (571)272-6197. The examiner can normally be reached Monday thru Friday; 8:30 AM to 5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SNIGDHA MAEWALL/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
Sep 08, 2025
Non-Final Rejection mailed — §103
Jan 08, 2026
Response Filed
May 15, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673140
BLADDER, URETER, KIDNEY, URETHRA, PROSTATE AND CATHETER ANTI-MICROBIAL, AND BIOFILM PREVENTION, REDUCTION AND TREATMENT
4y 0m to grant Granted Jul 07, 2026
Patent 12653854
Intra-Oral Nanoemulsion Including Monolayer Surfactant Bound Particles for Balancing Histamine Response
3y 0m to grant Granted Jun 16, 2026
Patent 12642757
USE OF COMBRETUM MICRANTHUM EXTRACT IN COSMETICS
5y 2m to grant Granted Jun 02, 2026
Patent 12616655
A TOPICAL ANTIBIOTIC CONTAINING PHARMACEUTICAL COMPOSITION FOR BACTERIAL INFECTIONS AND WOUND HEALING
4y 2m to grant Granted May 05, 2026
Patent 12599625
TREATMENT OF ARDS AND OTHER CONDITIONS CAUSED BY ACUTELY ELEVATED CYTOKINE LEVELS AND POST ARDS CHRONIC CYTOKINE PRODUCTION USING INHALED ANESTHETICS
3y 11m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
69%
With Interview (+10.4%)
3y 4m (~7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1064 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month